Sonendo (NYSE:SONX) is a medical technology company focused on advancing minimally invasive solutions in endodontics. The company’s flagship product, the GentleWave® System, employs advanced fluid dynamics and acoustic energy to more thoroughly clean and disinfect the root canal system during endodontic procedures. By harnessing Multisonic Ultracleaning® technology, Sonendo’s platform aims to improve clinical outcomes, reduce procedural time and preserve more tooth structure compared to conventional root canal methods.
The GentleWave System integrates a single-use handpiece with proprietary irrigation fluids and an integrated console, providing clinicians with an automated, controlled approach to canal cleaning. Sonendo continues to invest in product innovation and training, offering comprehensive clinical support and education through online modules, hands-on workshops and peer mentorship programs. The company’s commitment to research and development extends to exploring novel device enhancements and potential expansions into adjacent dental markets.
Headquartered in Laguna Hills, California, Sonendo markets its technology to endodontists and general dentists across North America, Europe and selected Asia-Pacific regions. Its distribution network combines direct sales forces with strategic partnerships, enabling the company to reach both established specialty practices and dental service organizations. By collaborating with academic institutions and professional societies, Sonendo seeks to drive broader adoption of its technology and elevate standards of patient care on a global scale.
Founded in 2006 and publicly listed on the New York Stock Exchange in 2020 under the ticker SONX, Sonendo was built upon foundational research in ultracleaning methodologies. The company is led by President and Chief Executive Officer Gregory R. Weiss, with Domenic C. Seravello serving as Chief Financial Officer. Under their guidance, Sonendo continues to focus on expanding its clinical portfolio, strengthening its intellectual property position and scaling its commercial efforts to address unmet needs in endodontic treatment.
